Share Price:

APNASPENAspen Pharmacare Hldgs13615265 (1.99%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Stephen Saad, Aspen Chief Executive address to President Ramaphosa and his delegation at Aspen’s flagship manufacturing site in Gqberha, Eastern Cape

“Our Aspen philosophy has always been to give purpose to life. This is best achieved by contributing meaningfully to others. Aspen has defined itself and continues to define itself as a company that serves humanity, particularly the most vulnerable amongst us. It was over a decade ago that we made a special announcement on a… Continue reading Stephen Saad, Aspen Chief Executive address to President Ramaphosa and his delegation at Aspen’s flagship manufacturing site in Gqberha, Eastern Cape

Aspen increases revenue by 17% to R18.6 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 30 December 2021. Stephen Saad, Aspen Group Chief Executive said, “The business has delivered pleasing results and has proven to be in robust shape over the past six… Continue reading Aspen increases revenue by 17% to R18.6 billion

Aspen concludes strategic partnership with US-based Avion Pharmaceuticals

Durban – United States-based Aspen Pharma USA Inc. and Aspen Global Incorporated, located in Mauritius, both wholly owned subsidiaries of Aspen Pharmacare Holdings Limited, have announced a license and commercialisation agreement with Avion Pharmaceuticals, LLC, a specialty pharmaceutical company, for the exclusive rights to relaunch Cenestin® in the USA. This is a New Drug Application… Continue reading Aspen concludes strategic partnership with US-based Avion Pharmaceuticals

Aspen announces agreement with Johnson & Johnson to manufacture investigational COVID-19 vaccine candidate

Stephen Saad Aspen Group Chief Executive

Durban, South Africa – Aspen is pleased to announce that one of its wholly-owned South African subsidiaries, Pharmacare Limited (which trades as “Aspen Pharmacare”), has entered into a preliminary agreement with Janssen Pharmaceuticals, Inc., and Janssen Pharmaceutica NV, two of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the technical transfer and proposed commercial… Continue reading Aspen announces agreement with Johnson & Johnson to manufacture investigational COVID-19 vaccine candidate

Aspen increases revenue by 9% to R38,6 billion

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced reviewed provisional Group financial results for the year ended 30 June 2020. COMMENTARY RESHAPING OF THE GROUP The recently announced agreement to divest the assets related to the commercialisation of Aspen’s Thrombosis business in Europe to Mylan… Continue reading Aspen increases revenue by 9% to R38,6 billion

Divestment of Aspen’s European Thrombosis Business to Mylan and withdrawal of cautionary

Johannesburg – Following the release of a cautionary announcement on 24 August 2020, Aspen is pleased to announce that, Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded an agreement in terms of which Mylan Ireland Limited (“Mylan”) will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis… Continue reading Divestment of Aspen’s European Thrombosis Business to Mylan and withdrawal of cautionary

Aspen scoops prized Adam Smith Treasury Award

Michael Shuttleworth, Aspen Group Treasury Executive

Aspen’s Group Treasury Team was recently recognised when they were awarded the highly acclaimed Adam Smith 2020 Best In Class Treasury Solution In Africa Award.

Aspen celebrates a decade of participation in Mandela Day

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is celebrating its 10th year of participation in the annual Mandela International Day (Mandela Day) campaign. Stephen Saad, Aspen Group Chief Executive said, “We participated in our first initiative in 2011 when we partnered with the Rekopane Inclusive Development… Continue reading Aspen celebrates a decade of participation in Mandela Day

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: